A central development of the company is the ESYSTA product system, which seamlessly stores insulin units and blood glucose readings and automatically transfers them to a digital diary. "Patients have access to their diabetes data at any time via the ESYSTA portal and the associated app, and authorized medical professionals can adjust the therapy based on this data," explains Dr. Horst Mertens. "ESYSTA is the only platform in the world to capture both blood sugar and insulin values, which allows for optimized therapy management."

Establishing ESYSTA in the market

Another unique feature of ESYSTA is the interoperability of the portal. It is compatible with more than 90% of all hardware components in the market and can process their digital signals, which significantly improves the quality of care. A personalized traffic light algorithm, based on artificial intelligence, allows doctors to efficiently monitor the data of many patients, which is invaluable given the limited time resources in the medical field. However, Emperra GmbH also faces significant challenges. The approval of their products by the relevant authorities is a complex process that requires a lot of time and resources. "Start-ups in the life sciences and health care are often founded by highly intelligent people," says Dr. Horst Mertens. "However, they often lack focus on commercialization and market penetration. This was one of the reasons why I came to Emperra. I use my many years of experience to specifically strengthen this area."

The company plans to launch its digital platform in January 2025, with a focus on patient-centered marketing. In Germany, where the middle class is traditionally strong, the company faces the challenge of serving global markets with its own resources. "For this, we need to approach serious global companies that will invest in Emperra to drive international expansion," says the COO and CBDO. The German market serves as a pilot market, and the strategic next step is expansion into France, Austria, and Belgium. Subsequently, four Arab countries will be targeted, as the proportion of people suffering from diabetes is particularly high there. In the long term, Emperra plans to conduct clinical trials in the USA to also penetrate this important market.

"Our motivation is clearly to help people with our digital diabetes treatment platform," emphasizes Dr. Horst Mertens. "If we successfully establish our ESYSTA system in the market, we can make life easier for many patients. Humanity is increasingly suffering from high-prevalence chronic diseases, with diabetes mellitus increasingly playing a central role. If blood sugar levels are not quickly and sustainably normalized, many complications can arise. Here, we want to utilize our platform to bring about real improvement. Our greatest strength lies in our team. We have a highly specialized, dedicated team of smart minds."